Protagonist Therapeutics, Inc Operating Income
Protagonist Therapeutics, Inc (PTGX) reported Operating Income of $158.77 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-05
- Protagonist Therapeutics, Inc operating income (loss) for the quarter ending 2026-06-30 was $158.77M.
- Protagonist Therapeutics, Inc operating income (loss) for the quarter ending 2026-03-31 was -$3.65M.
- Protagonist Therapeutics, Inc operating income (loss) for the quarter ending 2025-12-31 was -$50.35M, a 139.72% decline year-over-year.
- Protagonist Therapeutics, Inc operating income (loss) for the quarter ending 2025-09-30 was -$46.42M.
- Protagonist Therapeutics, Inc operating income (loss) for fiscal 2025 was -$158.13M, a 162.54% decline from fiscal 2024.
- Protagonist Therapeutics, Inc operating income (loss) for fiscal 2024 was $252.84M.
- Protagonist Therapeutics, Inc operating income (loss) for fiscal 2023 was -$93.65M.
- Protagonist Therapeutics, Inc operating income (loss) for fiscal 2022 was -$131.37M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $158.77M 10-Q · filed 2026-08-05 | $155.12M 10-Q · filed 2026-08-05 | $104.76M derived: sum of 3 quarters · filed 2026-08-05 | $58.34M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$3.65M 10-Q · filed 2026-05-05 | -$54.00M derived: sum of 2 quarters · filed 2026-05-05 | -$100.42M derived: sum of 3 quarters · filed 2026-05-05 | -$142.47M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$50.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$96.78M derived: sum of 2 quarters · filed 2026-02-25 | -$138.82M derived: sum of 3 quarters · filed 2026-08-05 | -$158.13M 10-K · filed 2026-02-25 |
| 2025-09-30 | -$46.42M 10-Q · filed 2025-11-06 | -$88.46M derived: sum of 2 quarters · filed 2026-08-05 | -$107.77M 10-Q · filed 2025-11-06 | $19.01M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$42.04M 10-Q · filed 2026-08-05 | -$61.35M 10-Q · filed 2026-08-05 | $65.43M derived: sum of 3 quarters · filed 2026-08-05 | $23.98M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$19.31M 10-Q · filed 2026-05-05 | $107.47M derived: sum of 2 quarters · filed 2026-05-05 | $66.02M derived: sum of 3 quarters · filed 2026-05-05 | $27.22M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $126.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $85.33M derived: sum of 2 quarters · filed 2026-02-25 | $46.53M derived: sum of 3 quarters · filed 2026-02-25 | $252.84M 10-K · filed 2026-02-25 |
| 2024-09-30 | -$41.45M 10-Q · filed 2025-11-06 | -$80.25M derived: sum of 2 quarters · filed 2025-11-06 | $126.06M 10-Q · filed 2025-11-06 | $149.11M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | -$38.79M 10-Q · filed 2025-08-06 | $167.52M 10-Q · filed 2025-08-06 | $190.56M derived: sum of 3 quarters · filed 2026-02-25 | $152.24M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $206.31M 10-Q · filed 2025-05-06 | $229.36M derived: sum of 2 quarters · filed 2026-02-25 | $191.03M derived: sum of 3 quarters · filed 2026-02-25 | $148.68M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $23.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$15.28M derived: sum of 2 quarters · filed 2026-02-25 | -$57.63M derived: sum of 3 quarters · filed 2026-02-25 | -$93.65M 10-K · filed 2026-02-25 |
| 2023-09-30 | -$38.33M 10-Q · filed 2024-11-07 | -$80.68M derived: sum of 2 quarters · filed 2024-11-07 | -$116.70M 10-Q · filed 2024-11-07 | -$153.22M derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-06-30 | -$42.35M 10-Q · filed 2024-08-06 | -$78.38M 10-Q · filed 2024-08-06 | -$114.89M derived: sum of 3 quarters · filed 2025-02-21 | -$147.19M derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-03-31 | -$36.02M 10-Q · filed 2024-05-07 | -$72.54M derived: sum of 2 quarters · filed 2025-02-21 | -$104.84M derived: sum of 3 quarters · filed 2025-02-21 | -$146.28M derived: sum of 4 quarters · filed 2025-02-21 |
| 2022-12-31 | -$36.52M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | -$68.82M derived: sum of 2 quarters · filed 2025-02-21 | -$110.26M derived: sum of 3 quarters · filed 2025-02-21 | -$131.37M 10-K · filed 2025-02-21 |
| 2022-09-30 | -$32.30M 10-Q · filed 2023-11-02 | -$73.75M derived: sum of 2 quarters · filed 2023-11-02 | -$94.86M 10-Q · filed 2023-11-02 | -$131.87M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$41.44M 10-Q · filed 2023-08-03 | -$62.55M 10-Q · filed 2023-08-03 | -$99.57M derived: sum of 3 quarters · filed 2024-02-27 | -$133.50M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | -$21.11M 10-Q · filed 2023-05-04 | -$58.13M derived: sum of 2 quarters · filed 2024-02-27 | -$92.05M derived: sum of 3 quarters · filed 2024-02-27 | -$122.94M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | -$37.02M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$70.94M derived: sum of 2 quarters · filed 2024-02-27 | -$101.82M derived: sum of 3 quarters · filed 2024-02-27 | -$125.84M 10-K · filed 2024-02-27 |
| 2021-09-30 | -$33.93M 10-Q · filed 2022-11-08 | -$64.81M derived: sum of 2 quarters · filed 2022-11-08 | -$88.83M 10-Q · filed 2022-11-08 | -$107.66M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-06-30 | -$30.88M 10-Q · filed 2022-08-04 | -$54.90M 10-Q · filed 2022-08-04 | -$73.73M derived: sum of 3 quarters · filed 2023-03-15 | -$81.50M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-03-31 | -$24.02M 10-Q · filed 2022-05-05 | -$42.85M derived: sum of 2 quarters · filed 2023-03-15 | -$50.62M derived: sum of 3 quarters · filed 2023-03-15 | -$68.84M derived: sum of 4 quarters · filed 2023-03-15 |
| 2020-12-31 | -$18.83M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$26.60M derived: sum of 2 quarters · filed 2023-03-15 | -$44.82M derived: sum of 3 quarters · filed 2023-03-15 | -$64.52M 10-K · filed 2023-03-15 |
| 2020-09-30 | -$7.77M 10-Q · filed 2021-11-03 | -$25.99M derived: sum of 2 quarters · filed 2021-11-03 | -$45.69M 10-Q · filed 2021-11-03 | -$62.98M derived: sum of 4 quarters · filed 2021-11-03 |
| 2020-06-30 | -$18.22M 10-Q · filed 2021-08-04 | -$37.91M 10-Q · filed 2021-08-04 | -$55.21M derived: sum of 3 quarters · filed 2021-08-04 | -$72.38M derived: sum of 4 quarters · filed 2021-08-04 |
| 2020-03-31 | -$19.70M 10-Q · filed 2021-05-04 | -$37.00M derived: sum of 2 quarters · filed 2021-05-04 | -$54.16M derived: sum of 3 quarters · filed 2021-05-04 | -$85.57M derived: sum of 4 quarters · filed 2021-05-04 |
| 2019-12-31 | -$17.30M 10-K · filed 2020-03-10 | -$34.47M derived: sum of 2 quarters · filed 2020-11-04 | -$65.87M derived: sum of 3 quarters · filed 2020-11-04 | -$80.52M 10-K · filed 2022-02-28 |
| 2019-09-30 | -$17.17M 10-Q · filed 2020-11-04 | -$48.57M derived: sum of 2 quarters · filed 2020-11-04 | -$63.22M 10-Q · filed 2020-11-04 | -$78.63M derived: sum of 4 quarters · filed 2020-11-04 |
| 2019-06-30 | -$31.41M 10-Q · filed 2020-08-06 | -$46.05M 10-Q · filed 2020-08-06 | -$61.47M derived: sum of 3 quarters · filed 2020-08-06 | -$70.86M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | -$14.65M 10-Q · filed 2020-05-07 | -$30.06M derived: sum of 2 quarters · filed 2020-05-07 | -$39.45M derived: sum of 3 quarters · filed 2020-05-07 | -$48.69M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | -$15.41M 10-K · filed 2020-03-10 | -$24.80M derived: sum of 2 quarters · filed 2020-03-10 | -$34.04M derived: sum of 3 quarters · filed 2020-03-10 | -$42.27M 10-K · filed 2021-03-10 |
| 2018-09-30 | -$9.39M 10-K · filed 2020-03-10 | -$18.63M derived: sum of 2 quarters · filed 2020-03-10 | -$26.86M 10-Q · filed 2019-11-06 | -$30.37M derived: sum of 4 quarters · filed 2020-03-10 |
| 2018-06-30 | -$9.24M 10-K · filed 2020-03-10 | -$17.47M 10-Q · filed 2019-08-07 | -$20.98M derived: sum of 3 quarters · filed 2020-03-10 | -$25.96M derived: sum of 4 quarters · filed 2020-03-10 |
| 2018-03-31 | -$8.23M 10-K · filed 2020-03-10 | -$11.74M derived: sum of 2 quarters · filed 2020-03-10 | -$16.72M derived: sum of 3 quarters · filed 2020-03-10 | -$31.85M derived: sum of 4 quarters · filed 2020-03-10 |
| 2017-12-31 | -$3.51M 10-K · filed 2019-03-12 | -$8.49M derived: sum of 2 quarters · filed 2019-03-12 | -$23.62M derived: sum of 3 quarters · filed 2019-03-12 | -$37.90M 10-K · filed 2020-03-10 |
| 2017-09-30 | -$4.98M 10-K · filed 2019-03-12 | -$20.11M derived: sum of 2 quarters · filed 2019-03-12 | -$34.38M 10-Q · filed 2018-11-06 | -$45.78M derived: sum of 4 quarters · filed 2019-03-12 |
| 2017-06-30 | -$15.13M 10-K · filed 2019-03-12 | -$29.40M 10-Q · filed 2018-08-07 | -$40.80M derived: sum of 3 quarters · filed 2019-03-12 | -$47.94M derived: sum of 4 quarters · filed 2019-03-12 |
| 2017-03-31 | -$14.27M 10-K · filed 2019-03-12 | -$25.67M derived: sum of 2 quarters · filed 2019-03-12 | -$32.81M derived: sum of 3 quarters · filed 2019-03-12 | -$39.90M derived: sum of 4 quarters · filed 2019-03-12 |
| 2016-12-31 | -$11.40M 10-K · filed 2018-03-07 | -$18.54M derived: sum of 2 quarters · filed 2018-03-07 | -$25.63M derived: sum of 3 quarters · filed 2018-03-07 | -$32.67M 10-K · filed 2019-03-12 |
| 2016-09-30 | -$7.14M 10-K · filed 2018-03-07 | -$14.23M derived: sum of 2 quarters · filed 2018-03-07 | -$21.27M 10-Q · filed 2017-11-07 | -$26.27M derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-06-30 | -$7.09M 10-K · filed 2018-03-07 | -$14.13M 10-Q · filed 2017-08-08 | -$19.13M derived: sum of 3 quarters · filed 2018-03-07 | -$23.15M derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-03-31 | -$7.04M 10-K · filed 2018-03-07 | -$12.04M derived: sum of 2 quarters · filed 2018-03-07 | -$16.06M derived: sum of 3 quarters · filed 2018-03-07 | -$19.14M derived: sum of 4 quarters · filed 2018-03-07 |
| 2015-12-31 | -$5.00M 10-K · filed 2017-03-07 | -$9.02M derived: sum of 2 quarters · filed 2017-03-07 | -$12.11M derived: sum of 3 quarters · filed 2017-03-07 | -$14.79M 10-K · filed 2018-03-07 |
| 2015-09-30 | -$4.02M 10-K · filed 2017-03-07 | -$7.10M derived: sum of 2 quarters · filed 2017-03-07 | -$9.79M 10-Q · filed 2016-11-14 | |
| 2015-06-30 | -$3.08M 10-K · filed 2017-03-07 | -$5.77M 10-Q · filed 2016-09-15 | ||
| 2015-03-31 | -$2.69M 10-K · filed 2017-03-07 | |||
| 2014-12-31 | -$9.32M 10-K · filed 2017-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |